LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

IVDR-Certified Mass Spectrometry Diagnostic System to Transform Detection of Monoclonal Gammopathies

By LabMedica International staff writers
Posted on 29 Aug 2023
Print article
Image: The IVDR-certified EXENT solution can transform diagnosis and monitoring of patients with monoclonal gammopathies (Photo courtesy of Thermo Fisher)
Image: The IVDR-certified EXENT solution can transform diagnosis and monitoring of patients with monoclonal gammopathies (Photo courtesy of Thermo Fisher)

Monoclonal gammopathies, including multiple myeloma, rank as the second most prevalent blood cancer globally, according to the 2020 report from the World Health Organization. Traditionally, treatment for these conditions involves monitoring M-protein levels, which can indicate the size of tumors. Despite significant treatment advancements, many patients are now achieving M-protein concentrations below detectable limits through standard methods. Yet, variations in disease progression persist within this patient group. Now, a new solution addresses this unmet clinical need for more sensitive analytical techniques that can differentiate between subsets of patients without resorting to invasive bone marrow biopsies prematurely.

Thermo Fisher Scientific (Waltham, MA, USA) has commercially launched the EXENT Solution after obtaining IVDR certification. This comprehensive and automated mass spectrometry system is designed to revolutionize diagnosis and assessment for individuals with monoclonal gammopathies. By utilizing the EXENT Solution, clinical laboratories can precisely measure, quantify, and monitor specific endogenous M-proteins and exogenous therapeutic monoclonal antibodies with heightened analytical sensitivity and precision in serum samples. The EXENT Solution has been developed to support the diagnosis of monoclonal gammopathies and facilitate the monitoring of patients with multiple myeloma and Waldenström's macroglobulinemia.

The EXENT Solution seamlessly integrates into routine laboratory workflows and comprises three integrated modules: EXENT-iP 500, an automated sample preparation instrument; EXENT-iX 500, a Matrix Assisted Laser Desorption Ionization - Time of Flight Mass Spectrometer (MALDI-ToF MS); and EXENT-iQ, an intelligent and user-friendly workflow software with data review capabilities. The system is complemented by the EXENT Immunoglobulin Isotypes (GAM) immunoassay, which is highly sensitive and specific for measuring and quantifying IgG, IgA, and IgM. The EXENT Solution is now available for commercial use in several countries, including Belgium, France, Germany, Italy, the Netherlands, Spain, and the United Kingdom.

“The EXENT Solution represents a significant breakthrough in innovation for the detection and monitoring of monoclonal immunoglobulins,” said Dr. Stephen Harding, Chief Scientific Officer, Protein Diagnostics, Thermo Fisher.

Related Links:
Thermo Fisher Scientific

Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.